After five years of follow-up in the phase 3 SEQUOIA study, first-line zanubrutinib treatment continues to demonstrate an improvement in progression-free survival in CLL versus BR.
Ivonescimab with chemotherapy elicited a median progression-free survival of 9.36 months in patients with locally advanced unresectable or metastatic triple-negative breast cancer.
China’s NMPA has approved perioperative pembrolizumab plus chemotherapy for select patients with resectable non–small cell lung cancer.
In an interview, Dr. Agostinetto delves into the findings of Dr. Souza, who shares the results of his research explaining why larotrectinib is positioned as…
Alexander Drilon and Alex Miles discuss the importance of shared decision making throughout the course of an NSCLC patient’s treatment.
Annals of Surgical Oncology – Fluid overload and hypovolemia promote postoperative complications in patients undergoing cytoreductive surgery for ovarian cancer. In the present study, postoperative…
This phase 1b/2 nonrandomized clinical trial evaluates whether equecabtagene autoleucel can benefit patients with relapsed or refractory multiple myeloma and determines the overall response rate…
An investigative JAK2 inhibitor demonstrated acceptable tolerability and early clinical activity in patients with JAK inhibitor–naive myelofibrosis.
This course is designed to provide in-depth academic teaching of the scientific principles underpinning x-ray and CT imaging, including descriptions of the imaging components,
This is a one-day course which covers the underpinning mathematics of medical imaging, comprising image formation, image processing techniques, human visual perception and image display…
Nature Cancer – Trumpp and colleagues develop a method to obtain long-term circulating tumor cell-derived organoids from individuals with metastatic breast cancer and identify the…
